ClinicalTrials.gg
CompletedNCT05258812Updated Feb 28, 2022

Cytopenias in Hospitalized Patients of Corona Virus Infection(COVID-19) During First and Other Waves

An observational study in Corona Virus Infection, sponsored by Fatima Memorial Hospital. Completed at 1 site in Pakistan. Open to participants aged 10 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-02-28.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fatima Memorial Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
202
Ages
10 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in COVID-19 with a site in Pakistan — 3 open to participants now, 4 under way, 2 of them phase 3. COVID-19 · Pakistan.

Enrollment
18th of 27
202 · median 373
Started
2020
with 61 others
Observational
27 of 98
1 open now
Registered
83rd of 98
by date

Among the 98 studies in COVID-19 with a site in Pakistan, this one is the 18th largest by enrollment of the 27 observational ones that give a count, is one of 62 that started in 2020, is one of 27 observational ones, and was the 83rd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 98 studies in COVID-19 with a site in Pakistan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 10 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in COVID-19 with a site in Pakistan, or all of them as a file.
02

Study summary

Demographic, Clinical and laboratory data as well as outcome of total 202 COVID-19 patients who were Polymerase Chain Reaction (PCR) positive and admitted in Fatima memorial Hospital, Lahore, Pakistan, was collected during first and other waves. Data of First wave is from May 2020 to July 2020, second wave from early November to Mid December 2020 and third wave from Mid march to June 2021. Investigator analyzed the data on basis of Systemic immune inflammatory index (SII) as well hematological parameters of First Wave were compared to other waves of COVID-19.

03

Conditions studied

  • Corona Virus Infection

Keywords

  • COVID-19
  • Cytopenia
  • Thrombocytopenia
  • Anemia
  • Leucopenia
04

In context

COVID-19 Reclassified

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

This study's enrollment of 202 is below the median of 268 across 3,209 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Fatima Memorial Hospital is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
10 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

COVID-19 Positive Hospitalized patients, of all genders and all age group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • COVID-19 Positive Hospitalized patients
  • All genders

Exclusion criteria

Exclusion Criteria:

  • Patients with Known hematological disorders
  • Patients with known chronic Liver Disease
06

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
202 participants (actual)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. Cytopenias in Hospitalized Patients of COVID-19 During First and Other waves

    extent of cytopenias is being measured in COVID-19 hospitalized patients.

    Time frame: 4 weeks

08

Study locations

1 site
  • Fatima memorial Hospital
    Lahore, Punjab 54000, Pakistan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Jun 2021, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Feb 28, 2022
StartActual
May 1, 2020
Primary completionActual
Jun 30, 2021
CompletionActual
Jun 30, 2021
Last update
Feb 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05258812
Lead sponsor
Fatima Memorial Hospital
Responsible party
Ambreen Kashif (Doctor, Fatima Memorial Hospital) — Principal investigator
First posted
Feb 28, 2022
Start date
May 1, 2020
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Feb 28, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion